The introduction of viral
protease inhibitors into combination antiretroviral regimens has
dramatically changed human immunodeficiency virus (HIV) therapeutics.
Capable of suppressing measurable viral loads to undetectable levels,
combination therapy has improved clinical status1 and
prolonged survival2,3 for many patients in the developed
world and is now firmly established as standard of care in the United
States.4 Recently, in an effort to afford these same
benefits to HIV-infected pregnant women, the US Public Health Service
has recommended that combination antiretroviral therapy be offered
during pregnancy as well.5 As an associated effect, several
centers that have implemented these recommendations have observed
perinatal HIV transmission rates approaching zero among women receiving
combination agents6- 9; by comparison, the HIV transmission
risk in untreated, non–breast-feeding women in the developed world is
14% to 25%,10 which can be reduced to as low as 5% with
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 32
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.